Efficacy and safety of ezetimibe in patients undergoing hemodialysis

Endocrine Journal

Volumn 57, Issue 11, 2010, Pages 1001-1005

  Hattori, Sachiko ^a   Hattori, Yoshiyuki ^b  

^a Tsunemicho Hospital   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Crp; Ezetimibe; Hemodialysis; Remnant

Indexed keywords

C REACTIVE PROTEIN; CAMPESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ABSORPTION; AGED; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; MALE; NOTE;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHYTOSTEROLS; RENAL DIALYSIS; RENAL INSUFFICIENCY; TRIGLYCERIDES;

EID: 78649782190     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-165     Document Type: Note

References (15)

1. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP (1994) Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9: 1136-1142.
2. Cheung AK (2009) Is lipid control necessary in hemodialysis patients? Clin J Am Soc Nephrol 4 Suppl 1: S95-101.
3. Shoji T, Nishizawa Y (2006) Plasma lipoprotein abnormalities in hemodialysis patients--clinical implications and therapeutic guidelines. Ther Apher Dial 10: 305-315.
4. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-407.
5. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373: 1175-1182.
6. Calderon RM, Cubeddu LX, Goldberg RB, Schiff ER (2010) Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma. Mayo Clin Proc 85: 349-356.
7. Cham S, Evans MA, Denenberg JO, Golomb BA (2010) Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacother 30: 541-553.
8. Grundy SM (2005) The issue of statin safety: where do we stand? Circulation 111: 3016-3019.
9. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM (1996) Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 275: 128-133.
10. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP (2004) Niemann Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303: 1201-1204.
11. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA (2005) The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 102: 8132-8137.
12. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA (2006) Cholesterol and glucose metabolism and recur rent cardiovascular events among the elderly: a prospective study. J Am Coll Cardiol 48: 708-714.
13. Miettinen TA, Ahrens EH Jr, Grundy SM (1965) Quantitative isolation and gas-liquid chromatographic analysisof total dietary and fecal neutral steriods. J Lipid Res 6: 411-424.
14. Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR (2006) Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J Lipid Res 47: 2575-2580.
15. Montecucco F, Quercioli A, Mach F (2009) Ezetimibe/simvastatin. Expert Opin Drug Saf 8: 715-725.